

S 516

Prescription Drug Monitoring Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Feb 14, 2019

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Feb 14, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/senate-bill/516>

Sponsor

Name: Sen. Klobuchar, Amy [D-MN]

Party: Democratic • **State:** MN • **Chamber:** Senate

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. King, Angus S., Jr. [I-ME]	I · ME		Feb 14, 2019
Sen. Manchin, Joe, III [D-WV]	D · WV		Feb 14, 2019
Sen. Portman, Rob [R-OH]	R · OH		Feb 14, 2019

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Feb 14, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 3974	Identical bill	Jul 26, 2019: Referred to the Subcommittee on Health.

Prescription Drug Monitoring Act of 2019

This bill expands the notification and reporting requirements with respect to potentially addictive prescription drugs for states receiving funds for a Prescription Drug Monitoring Program (PDMP). Dispensers of these drugs, which includes substances listed in schedule II, III, or IV of the Controlled Substances Act, must consult with the PDMP before starting treatment involving such drugs and report each prescription of such drugs to the PDMP within 24 hours.

The state agency administering a PDMP must analyze reported data for patterns of controlled substance misuse or abuse and provide certain information to law enforcement, the public, and other states.

Actions Timeline

- **Feb 14, 2019:** Introduced in Senate
- **Feb 14, 2019:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.